SRR27320684
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 61.08333333
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- ANDROGEN_RESPONSE+0.230
- MITOTIC_SPINDLE+0.230
- GLYCOLYSIS+0.220
- CHOLESTEROL_HOMEOSTASIS+0.150
- APICAL_SURFACE+0.140
- G2M_CHECKPOINT+0.140
- UNFOLDED_PROTEIN_RESPONSE+0.140
- E2F_TARGETS+0.120
- PI3K_AKT_MTOR_SIGNALING+0.120
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.480
- TNFA_SIGNALING_VIA_NFKB-0.470
- ANGIOGENESIS-0.460
- INTERFERON_GAMMA_RESPONSE-0.390
- HEDGEHOG_SIGNALING-0.380
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- OXIDATIVE_PHOSPHORYLATION-0.310
- INTERFERON_ALPHA_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR9879267 | — | cohortA1 | 0.828 |
| 2 | TCGA-62-A46O-01A-11R-A24H-07 | — | cohortA4 | 0.804 |
| 3 | TCGA-GU-A42P-01A-11R-A23W-07 | — | — | 0.796 |
| 4 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.796 |
| 5 | TCGA-FJ-A3ZE-01A-11R-A23N-07 | — | — | 0.793 |
| 6 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.789 |
| 7 | TCGA-ZF-A9RL-01A-11R-A38B-07 | — | — | 0.789 |
| 8 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.789 |
| 9 | R360 | — | — | 0.788 |
| 10 | 3bb03dc9-6daf-42ef-95d6-cdf726f926e8 | — | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |